Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Tuomela, Johanna M ^a   Valta, Maija P ^a   Väänänen, Kalervo ^a   Härkönen, Pirkko L ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; MESSENGER RNA; RNA; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CD34 SELECTION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE TUMOR; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; CANCER INVASION; CANCER TRANSPLANTATION; CELL DIVISION; DRUG EFFECT; DRUG SCREENING; GENETICS; GERMFREE ANIMAL; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADENOCARCINOMA; ALENDRONATE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; HUMANS; LYMPHATIC METASTASIS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RNA, MESSENGER; RNA, NEOPLASM; SPECIFIC PATHOGEN-FREE ORGANISMS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42349098792     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-8     Document Type: Article

References (64)

1. Gronberg H Prostate cancer epidemiology Lancet 2003, 361(9360):859-864. 10.1016/S0140-6736(03)12713-4 12642065
2. Rassweiler J Schulze M Teber D Marrero R Seemann O Rumpelt J Frede T Laparoscopic radical prostatectomy with the Heilbronn technique: oncological results in the first 500 patients J Urol 2005, 173(3):761-764. 10.1097/01.ju.0000153486.94741.e5 15711264
3. Coleman RE Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 2006, 12(20 Pt 2):6243s-6249s. 10.1158/1078-0432.CCR-06-0931 17062708
4. Roy-Burman P Wu H Powell WC Hagenkord J Cohen MB Genetically defined mouse models that mimic natural aspects of human prostate cancer development Endocr Relat Cancer 2004, 11(2):225-254. 10.1677/ erc.0.0110225 15163300
5. Stephenson RA Dinney CP Gohji K Ordonez NG Killion JJ Fidler IJ Metastatic model for human prostate cancer using orthotopic implantation in nude mice J Natl Cancer Inst 1992, 84(12):951-957. 10.1093/jnci/ 84.12.951 1378502
6. Shevrin DH Gorny KI Kukreja SC Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice Prostate 1989, 15(2):187-194. 10.1002/pros.2990150212 2529482
7. Wu TT Sikes RA Cui Q Thalmann GN Kao C Murphy CF Yang H Zhau HE Balian G Chung LW Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines Int J Cancer 1998, 77(6):887-894. 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z 9714059
8. Kanis JA Powles T Paterson AH McCloskey EV Ashley S Clodronate decreases the frequency of skeletal metastases in women with breast cancer Bone 1996, 19(6):663-667. 10.1016/S8756-3282(96)00285-2 8968035
9. McCloskey EV Dunn JA Kanis JA MacLennan IC Drayson MT Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma Br J Haematol 2001, 113(4):1035-1043. 10.1046/j.1365-2141.2001.02851.x 11442499
10. Guise TA Bone loss and fracture risk associated with cancer therapy Oncologist 2006, 11(10):1121-1131. 10.1634/theoncologist.11-10-1121 17110632
11. Reginster JY Sarlet N The treatment of severe postmenopausal osteoporosis: A review of current and emerging therapeutic options Treat Endocrinol 2006, 5(1):15-23. 10.2165/00024677-200605010-00003 16396515
12. Virtanen SS Vaananen HK Harkonen PL Lakkakorpi PT Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway Cancer Res 2002, 62(9):2708-2714. 11980672
13. van der Pluijm G Vloedgraven H van Beek E van der Wee-Pals L Lowik C Papapoulos S Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro J Clin Invest 1996, 98(3):698-705. 507479 8698861 10.1172/JCI118841
14. Boissier S Magnetto S Frappart L Cuzin B Ebetino FH Delmas PD Clezardin P Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices Cancer Res 1997, 57(18):3890-3894. 9307266
15. Stearns ME Wang M Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice Clin Exp Metastasis 1998, 16(8):693-702. 10.1023/A:1006524610591 10211982
16. Jagdev SP Coleman RE Shipman CM Rostami HA Croucher PI The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel Br J Cancer 2001, 84(8):1126-1134. 10.1054/bjoc.2001.1727 11308265
17. Fromigue O Lagneaux L Body JJ Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 2000, 15(11):2211-2221. 10.1359/ jbmr.2000.15.11.2211 11092402
18. Fournier P Boissier S Filleur S Guglielmi J Cabon F Colombel M Clezardin P Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 2002, 62(22):6538-6544. 12438248
19. Wakchoure S Merrell MA Aldrich W Millender-Swain T Harris KW Triozzi P Selander KS Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo Clin Cancer Res 2006, 12(9):2862-2868. 10.1158/ 1078-0432.CCR-05-2766 16675582
20. Padalecki SS Guise TA Actions of bisphosphonates in animal models of breast cancer Breast Cancer Res 2002, 4(1):35-41. 138714 11879558 10.1186/bcr415
21. Hiraga T Williams PJ Mundy GR Yoneda T The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases Cancer Res 2001, 61(11):4418-4424. 11389070
22. Hashimoto K Morishige K Sawada K Tahara M Kawagishi R Ikebuchi Y Sakata M Tasaka K Murata Y Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model Cancer Res 2005, 65(2):540-545. 15695397
23. Hiraga T Williams PJ Ueda A Tamura D Yoneda T Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model Clin Cancer Res 2004, 10(13):4559-4567. 10.1158/1078-0432.CCR-03-0325 15240548
24. Yamagishi S Abe R Inagaki Y Nakamura K Sugawara H Inokuma D Nakamura H Shimizu T Takeuchi M Yoshimura A Bucala R Shimizu H Imaizumi T Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling Am J Pathol 2004, 165(6):1865-1874. 1618714 15579431
25. Giraudo E Inoue M Hanahan D An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 2004, 114(5):623-633. 514591 15343380
26. Ory B Heymann MF Kamijo A Gouin F Heymann D Redini F Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice Cancer 2005, 104(11):2522-2529. 10.1002/ cncr.21530 16270320
27. Wood J Bonjean K Ruetz S Bellahcene A Devy L Foidart JM Castronovo V Green JR Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 2002, 302(3):1055-1061. 10.1124/ jpet.102.035295 12183663
28. Powles T Paterson S Kanis JA McCloskey E Ashley S Tidy A Rosenqvist K Smith I Ottestad L Legault S Pajunen M Nevantaus A Mannisto E Suovuori A Atula S Nevalainen J Pylkkanen L Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer J Clin Oncol 2002, 20(15):3219-3224. 10.1200/JCO.2002.11.080 12149294
29. Diel IJ Solomayer EF Costa SD Gollan C Goerner R Wallwiener D Kaufmann M Bastert G Reduction in new metastases in breast cancer with adjuvant clodronate treatment N Engl J Med 1998, 339(6):357-363. 10.1056/ NEJM199808063390601 9691101
30. Saarto T Blomqvist C Virkkunen P Elomaa I Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial J Clin Oncol 2001, 19(1):10-17. 11134190
31. Janik P Briand P Hartmann NR The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors Cancer Res 1975, 35(12):3698-3704. 1192428
32. Jackson DG Prevo R Clasper S Banerji S LYVE-1, the lymphatic system and tumor lymphangiogenesis Trends Immunol 2001, 22(6):317-321. 10.1016/ S1471-4906(01)01936-6 11377291
33. Ruohola JK Viitanen TP Valve EM Seppanen JA Loponen NT Keskitalo JJ Lakkakorpi PT Harkonen PL Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells Cancer Res 2001, 61(10):4229-4237. 11358849
34. Chomczynski P Sacchi N Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction Anal Biochem 1987, 162(1):156-159. 10.1016/0003-2697(87)90021-2 2440339
35. Joukov V Pajusola K Kaipainen A Chilov D Lahtinen I Kukk E Saksela O Kalkkinen N Alitalo K A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases Embo J 1996, 15(7):1751. 450088 8612600
36. Berquin IM Min Y Wu R Wu H Chen YQ Expression signature of the mouse prostate J Biol Chem 2005, 280(43):36442-36451. 10.1074/jbc.M504945200 16055444
37. Li J Wang E Rinaldo F Datta K Upregulation of VEGF-C by androgen depletion: The involvement of IGF-IR-FOXO pathway Oncogene 2005, 24(35):5510-5520. 10.1038/sj.onc.1208693 15897888
38. Wong SY Haack H Crowley D Barry M Bronson RT Hynes RO Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis Cancer Res 2005, 65(21):9789-9798. 10.1158/ 0008-5472.CAN-05-0901 16267000
39. Bader P Burkhard FC Markwalder R Studer UE Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003, 169(3):849-854. 10.1097/01.ju.0000049032.38743.c7 12576797
40. Oades GM Senaratne SG Clarke IA Kirby RS Colston KW Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells J Urol 2003, 170(1):246-252. 10.1097/01.ju.0000070685.34760.5f 12796698
41. Saad F Gleason DM Murray R Tchekmedyian S Venner P Lacombe L Chin JL Vinholes JJ Goas JA Zheng M Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 2004, 96(11):879-882. 15173273
42. Saad F Gleason DM Murray R Tchekmedyian S Venner P Lacombe L Chin JL Vinholes JJ Goas JA Chen B A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 2002, 94(19):1458-1468. 12359855
43. Parker CC Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 2004, 96(19):1480-1481. 15467039
44. Parker CC The role of bisphosphonates in the treatment of prostate cancer BJU Int 2005, 95(7):935-938. 10.1111/j.1464-410X.2005.05441.x 15839907
45. Stearns ME Wang M Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice Invasion Metastasis 1996, 16(3):116-131. 9186547
46. Suri S Monkkonen J Taskinen M Pesonen J Blank MA Phipps RJ Rogers MJ Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity Bone 2001, 29(4):336-343. 10.1016/S8756-3282(01)00589-0 11595616
47. Muller S Migianu E Lecouvey M Kraemer M Oudar O Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro Anticancer Res 2005, 25(4):2655-2660. 16080508
48. Zhou Z Guan H Duan X Kleinerman ES Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma Cancer 2005, 104(8):1713-1720. 10.1002/ cncr.21383 16121404
49. Salven P Lymboussaki A Heikkila P Jaaskela-Saari H Enholm B Aase K von Euler G Eriksson U Alitalo K Joensuu H Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors Am J Pathol 1998, 153(1):103-108. 1852959 9665470
50. Stearns ME Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells Clin Exp Metastasis 1998, 16(4):332-339. 10.1023/A:1006513413583 9626812
51. Achen MG McColl BK Stacker SA Focus on lymphangiogenesis in tumor metastasis Cancer Cell 2005, 7(2):121-127. 10.1016/j.ccr.2005.01.017 15710325
52. Karpanen T Egeblad M Karkkainen MJ Kubo H Yla-Herttuala S Jaattela M Alitalo K Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth Cancer Res 2001, 61(5):1786-1790. 11280723
53. Tsurusaki T Kanda S Sakai H Kanetake H Saito Y Alitalo K Koji T Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis Br J Cancer 1999, 80(1-2):309-313. 10.1038/sj.bjc.6690356 10390013
54. Mattila MM Ruohola JK Karpanen T Jackson DG Alitalo K Harkonen PL VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors Int J Cancer 2002, 98(6):946-951. 10.1002/ ijc.10283 11948478
55. Skobe M Hawighorst T Jackson DG Prevo R Janes L Velasco P Riccardi L Alitalo K Claffey K Detmar M Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Nat Med 2001, 7(2):192-198. 10.1038/84643 11175850
56. Carmeliet P Jain RK Angiogenesis in cancer and other diseases Nature 2000, 407(6801):249-257. 10.1038/35025220 11001068
57. Kimbro KS Simons JW Hypoxia-inducible factor-1 in human breast and prostate cancer Endocr Relat Cancer 2006, 13(3):739-749. 10.1677/ erc.1.00728 16954428
58. Caraglia M Santini D Marra M Vincenzi B Tonini G Budillon A Emerging anti-cancer molecular mechanisms of aminobisphosphonates Endocr Relat Cancer 2006, 13(1):7-26. 10.1677/erc.1.01094 16601276
59. Monkkonen H Auriola S Lehenkari P Kellinsalmi M Hassinen IE Vepsalainen J Monkkonen J A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates Br J Pharmacol 2006, 147(4):437-445. 1616989 16402039 10.1038/sj.bjp.0706628
60. Oades GM Coxon J Colston KW The potential role of bisphosphonates in prostate cancer Prostate Cancer Prostatic Dis 2002, 5(4):264-272. 10.1038/sj.pcan.4500607 12627210
61. Merrell MA Wakchoure S Lehenkari PP Harris KW Selander KS Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells Eur J Pharmacol 2007.
62. Frith JC Rogers MJ Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro J Bone Miner Res 2003, 18(2):204-212. 10.1359/jbmr.2003.18.2.204 12568397
63. Kaida H Ishibashi M Baba K Nishida H Matsuoka K Hayabuchi N Extraosseous uptake of metastatic lymph nodes of ureteral cancer on 99Tcm hydroxymethylene diphosphonate bone scintigraphy Br J Radiol 2004, 77(922):869-870. 10.1259/bjr/14405146 15483000
64. Shih WJ DeLand FH Domstad PA Johnston EH Extraosseous localization of 99mTc-MDP in ganglioneuroblastoma Eur J Nucl Med 1982, 7(7):336-338. 10.1007/BF00253434 6214400